Characterization of MK-4166, a clinical agonistic mAb that targets human GITR and inhibits the generation and activity of Tregs. (December 2016) - Sukumar, S.; Wison, D.; Yu, Y.; Wong, J.; Naravula, S.; Ermakov, G.; Bhagwat, B.; Grein, J.; Churakova, T.; Mangadu, R.; Sriram, V.; Bailey, W.; et al.